Pharmafile Logo
Pharmafocus logo
Advanced Search

trial failure

Showing 15 posts of 38 posts found.

shutterstock_212432119

Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure

September 17, 2019
Manufacturing and Production, Research and Development Acceleron, pharma, trial failure

Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …

News

Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures

May 28, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure

Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …

News
abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

May 20, 2019
Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …

News
boehringer_biberach_germany_copy

Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke

May 20, 2019
Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure

Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …

News

BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme

May 10, 2019
Medical Communications, Research and Development BMS, Bristol-Myers Squibb, glioblastoma multiforme, pharma, trial failure

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating …

News
shutterstock_212432119

Allergy Therapeutics’ adjuvanted birch allergoid drug shocks with Phase 3 failure

March 18, 2019
Research and Development, Sales and Marketing allergy, allergy therapeutics, pharma, trial failure

UK-based biotech firm Allergy Therapeutics has been left disappointed after it became evident that its adjuvanted birch allergoid product failed …

News
lilly_building_with_american_flag_web

Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma

January 21, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure

Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …

News
shutterstock_212035546

Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD

January 15, 2019
Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma

Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …

News
stocks1

Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

November 27, 2018
Manufacturing and Production, Research and Development asthma, pharma, trial failure, vectura

Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, …

News
michel_porro-getty_images

Zynerba’s cannabis-based transdermal patch fails at Phase 1, shares slide 21%

July 6, 2018
Medical Communications, Research and Development GW Pharma, Zynerba, cannabidinol, cannabinol, cannabis, pharma, trial failure

As public focus on the issue of medicinal cannabis continues to grow, Zynerba Pharmaceuticals has announced that its transdermal tetrahydrocannabinol …

News
shutterstock_36423250

Summit Pharma axes Duchenne drug after Phase 2 failures

June 28, 2018
Research and Development Duchenne Muscular Dystrophy, Summit Pharmaceuticals, pharma, trial failure

Summit Therapeutics has revealed it is to terminate development of its Duchenne muscular dystrophy (DMD) drug ezutromid after it failed …

News
merckincweb

Keytruda combo fails at Phase 3 in metastatic melanoma

April 9, 2018
Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure

Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …

News
shutterstock_159488225

Anthera pulls the plug on Sollpura after Phase 3 failure, shares plummet 84%

March 13, 2018
Manufacturing and Production, Research and Development Anthera, Eli Lilly, Sollpura, pharma, trial failure

Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after …

News
vbl-big

VBL Therapeutics’ shares plummet on Phase 3 glioblastoma failure

March 9, 2018
Medical Communications, Research and Development VBL, VBL Therapeutics, glioblastoma, pharma, trial failure

Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, …

News
dermira_logo

Dermira terminates acne drug after Phase 3 failure, wiping $667m from market value

March 5, 2018
Manufacturing and Production, Research and Development Dermira, acne, pharma, trial failure

Skin specialist biopharma firm Dermira has seen its stock crash and burn following the announcement that it plans to terminate …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023